News

Promising Results from PoNS Therapy for Gait Challenges

Promising Results from PoNS Therapy for Gait Challenges

Helius Medical Technologies Reports PoNS Therapy Breakthroughs

Helius Medical Technologies, Inc. (NASDAQ: HSDT), a pioneer in neurotechnology, has unveiled significant findings from the PoNS Therapeutic Experience Program, known as PoNSTEP. This study has revealed the Portable Neuromodulation Stimulator (PoNS) therapy's capacity to enhance gait in individuals suffering from Multiple Sclerosis (MS). With a market presence valued at $3.84 million, Helius is keen on addressing gait deficits experienced by MS patients, showcasing a commitment to advancing neurological health.

The PoNSTEP Study: Long-Term Efficacy Ignited

The PoNSTEP study encompassed 43 participants diagnosed with mild to moderate gait impairments due to MS. The results demonstrated an impressive average improvement of 5.00 on the Dynamic Gait Index (DGI) by the 14th week, supported by statistically valid findings. This improvement showcases PoNS therapy's promise in instigating sustainable progress for patients who struggle with mobility due to neurological disorders.

Adherence to Therapy: A Key Factor

The research underlined that commitment to the therapy regimen is critical for success. During the second phase of the study, an admirable average adherence rate of 71% was noted, leading to remarkable improvements in scores. Participants maintaining higher adherence of 85% or above experienced a mean improvement of 3.7 points in DGI, compared with just 2.0 points for those less compliant. This strong correlation highlights the necessity of consistency in treatment for optimal outcomes.

Long-Lasting Results Indicate Therapeutic Promise

When the participants were re-evaluated six months later, only one out of 28 showed a decline of 30% or more in their DGI scores. This finding strongly suggests that the therapeutic benefits of PoNS therapy are not just temporary but can provide enduring improvements in gait functionality. This research illuminates the role of neuroplasticity in maintaining these enhancements over time, reflecting a positive shift in how MS can be managed.

Insights from Leadership on PoNS Therapy

Dr. Antonella Favit-Van Pelt, Chief Medical Officer of Helius, expressed that the outcomes of the PoNSTEP study represent a pivotal step in understanding how neuromodulation can play a role in rehabilitating gait function. Meanwhile, Helius President and CEO, Dane Andreeff, highlighted his satisfaction with the evident effectiveness of PoNS therapy and reiterated the necessity of treatment compliance for achieving the best results.

Current Accessibility and Future Directions

Currently, PoNS therapy is prescribed in the United States for patients aged 22 and older dealing with gait deficits due to MS. It has also gained acceptance in Canada and Australia for other medical indications. The promising results from the ongoing studies are set to be presented at forthcoming scientific conferences, further advocating for the potential of PoNS therapy to improve the quality of life for individuals with neurological issues.

Market Reactions and Stock Performance

In light of these developments, investor sentiment towards Helius Medical Technologies has been notably favorable. The stock has seen significant returns, with a remarkable increase exceeding 21% in the past week and an impressive 53% rise year-to-date. Such market movements reflect growing confidence in Helius's research advancements and product efficacy.

Ongoing Innovations and Developments

Additionally, Helius Medical Technologies is making strides in its stroke registrational program, having surpassed initial enrollment expectations, a sign of progress in showcasing the effectiveness of PoNS. The company has also secured final Medicare payment rates from the Centers for Medicare and Medicaid Services (CMS) for the PoNS device. This achievement marks a notable milestone, even amidst debates concerning pricing determinations.

Future Prospects for Helius

Looking ahead, preliminary results from the PoNSTEP study signify significant enhancements in DGI scores among MS patients utilizing PoNS therapy. Helius is gearing up for submission to the FDA for stroke treatment authorization and is also investigating the application of PoNS for traumatic brain injury patients. Despite facing a notable revenue dip of 36.62% over the past year, Helius maintains a robust financial outlook, securing stability through a successful public offering.

Frequently Asked Questions

What is PoNS therapy?

PoNS therapy is a non-invasive treatment using a Portable Neuromodulation Stimulator to aid in improving gait deficits, particularly in MS patients.

How effective is PoNS therapy based on recent studies?

The recent PoNSTEP study indicated a significant improvement in gait, with a mean increase of 5.00 in DGI scores after 14 weeks of treatment.

What role does treatment adherence play in PoNS therapy?

Adherence to the therapy regimen is crucial for effectiveness; higher compliance rates correlate with greater improvements in gait scores.

What are the future plans for Helius Medical Technologies?

Helius is focused on expanding the use of PoNS therapy for additional applications, including stroke and traumatic brain injury.

Has Helius seen any recent market success?

Yes, Helius has experienced significant stock performance, with a 21% increase in a week and a 53% increase year-to-date, reflecting positive market sentiment.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 30

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 68

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 144

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 33

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
Lithium's Next Leg Depends on Storage, Not EV Hype

Updated Category News Views 67

Grid batteries are quietly becoming lithium’s second engine, and that matters more than another flashy electric-vehicle sales headline. The market is projected to rise from $40.87 billion in 2026 to $57.77 billion by 2031, a 7.2% compound annual growth rate. Respectable growth, certainly. But this is not a straight line, and anybody treating a five-year market forecast...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 232

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Rochester Truck Crashes Demand a Different Liability Map

Updated Category News Views 50

An 80,000-pound rig does not leave anybody the luxury of treating a wreck like a bent-fender dispute. That is the uncomfortable point behind Rochester attorney John Wright's discussion of truck crashes around I-390 and I-490. The physical damage may be obvious, but the legal story can be buried in dispatch systems, maintenance files, driver logs and corporate decisions...

Continue Reading
Rokt's 164% Growth Shows Checkout Ads Have Real Muscle

Updated Category News Views 65

Checkout screens have become valuable real estate, and Rokt is planting a flag right in the middle of them. The New York ecommerce technology company landed on Deloitte's 2026 Technology Fast 500 after posting 164% revenue growth from 2022 through 2025. That is a meaningful number, not decorative corporate confetti, especially in a digital-ad market where plenty of...

Continue Reading
Miami I20 Tests Appetite for Long-Term U.S. Capital

Updated Category News Views 124

Five days in a Miami airport hotel may not sound like the machinery of national investment policy, yet the guest list for the inaugural I20 Summit is serious enough to make capital markets sit up. From December 11 through 15, the Sovereign Wealth Fund Institute plans to bring sovereign funds, pensions, endowments, family offices, business leaders and U.S....

Continue Reading
Radiology Staffing Gap Deepens as Imaging Demand Rises

Updated Category News Views 9

An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...

Continue Reading

Top 5 Most Recently Viewed Articles

Ping An Healthcare Delivers Impressive Growth in Interim Results

Updated Category News Views 186

Impressive Interim Results from Ping An Healthcare Ping An Healthcare and Technology Company Limited (the "Company"; Stock Code: 1833.HK) has announced robust interim results for the six-month period ending June 30, showing significant progress following its return to profitability. Throughout this period, the Company has demonstrated strong revenue growth and a notable...

Continue Reading
Market Insights: Trends in Precious Metals and Sector Performance

Updated Category News Views 201

Understanding Market Dynamics and Precious Metals The current landscape of Wall Street might appear quiet at first glance, especially during the lull between holidays. However, beneath this surface lies a surge of activity, particularly in the realm of precious metals. Investors are keenly observing the uptick in volatility, specifically concerning silver and other key...

Continue Reading
Discover the Most Popular Pet Breeds of 2025: Insights and Trends

Updated Category News Views 409

Understanding the 2025 Top Pet Breeds The bond between pets and their owners often mirrors our own personalities and values. Recent insights reveal that 8 out of 10 pet parents believe a dog breed reflects a person's character. Across different breeds, qualities such as friendliness, sociability, and playfulness top the charts when pet parents make their choices. The...

Continue Reading
Amicus Therapeutics Engages Investors at Key Conferences Soon

Updated Category News Views 129

Amicus Therapeutics to Present at Upcoming Investor Conferences Amicus Therapeutics (Nasdaq: FOLD), a dedicated player in the biotechnology landscape, has announced its forthcoming participation in significant investor conferences this September, showcasing its unwavering commitment to fostering investor relations. Details of the Upcoming Presentations The company has...

Continue Reading
Understanding RPM Intl's P/E Ratio in Market Context

Updated Category News Views 206

Understanding RPM Intl's Stock Performance Currently, RPM Intl Inc. (NYSE: RPM) is experiencing a share price of $123.50, reflecting a modest increase of 0.36%. This uptick is notable amidst a turbulent month, where the stock has decreased by 11.21%. However, when we look back over the past year, we see a positive trend, with the stock appreciating by 16.26%. Investors...

Continue Reading